Bedaquiline
Based on 56 publication(s) in Google Scholar
Bedaquiline (TMC207) is a diarylquinoline agent and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-agent resistant tuberculosis.
For research use only. We do not sell to patients.
- Purity: 99.98%
- CAS No.: 843663-66-1
- Formula: C32H31BrN2O2
- Molecular Weight:555.50
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Antibacterial Compound Library
HY-L049
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Rare Diseases Drug Library
HY-L102
-
EMA-Approved Drug Library
HY-L116
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Anti-tuberculosis Compound Library
HY-L142
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Bedaquiline
More- Cell. 2023 May 11;186(10):2176-2192.e22. [Abstract]
- Nat Commun. 2025 May 10;16(1):4366. [Abstract]
- Nat Commun. 2021 Jun 21;12(1):3816. [Abstract]
- Autophagy. 2026 Mar 5. [Abstract]
- Adv Sci (Weinh). 2026 Apr;13(21):e13341. [Abstract]
- Eur J Med Chem. 2022 Nov 15:242:114639. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Int J Pharm. 2024 Mar 25:653:123920. [Abstract]
- Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
- Commun Biol. 2025 Feb 6;8(1):187. [Abstract]
- Pharmaceuticals (Basel). 2023 Sep 15;16(9):1309. [Abstract]
- Front Cell Infect Microbiol. 2016 Nov 8:6:145. [Abstract]
- mBio. 2021 Jun 29;12(3):e0108821. [Abstract]
- Antibiotics (Basel). 2026 Jun 9;15(6):590. [Abstract]
- Nanomedicine. 2025 Apr;20(8):777-789. [Abstract]
- Antimicrob Agents Chemother. 2025 Sep 11:e0079525. [Abstract]
- Antimicrob Agents Chemother. 2025 May 27:e0184724. [Abstract]
- Antimicrob Agents Chemother. 2025 May 23:e0024925. [Abstract]
- mLife. 2025 Apr 15;4(2):155-168. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0105124. [Abstract]
- Antimicrob Agents Chemother. 2024 Oct 29:e0094524. [Abstract]
- Antimicrob Agents Chemother. 2023 Feb 16;67(2):e0145922. [Abstract]
- Front Microbiol. 2021 Feb 25;12:647611. [Abstract]
- Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0095621. [Abstract]
- Antimicrob Agents Chemother. 2021 Mar 18;65(4):e01445-20. [Abstract]
- Antimicrob Agents Chemother. 2020 Mar 24;64(4):e02404-19. [Abstract]
- Antimicrob Agents Chemother. 2020 Jan 27;64(2):e01540-19. [Abstract]
- Antimicrob Agents Chemother. 2019 Sep 23;63(10):e01191-19. [Abstract]
- Front Microbiol. 2018 Aug 15:9:1898. [Abstract]
- J Biol Chem. 2024 Feb;300(2):105618. [Abstract]
- Microbiol Spectr. 2026 Apr 7;14(5):e0380525. [Abstract]
- ACS Infect Dis. 2025 Apr 1. [Abstract]
- ACS Infect Dis. 2024 Sep 13;10(9):3222-3232. [Abstract]
- ACS Infect Dis. 2024 Feb 9;10(2):513-526. [Abstract]
- Microbiol Spectr. 2023 Dec 12;11(6):e0228223. [Abstract]
- ACS Chem Biol. 2022 Jan 21;17(1):39-53. [Abstract]
- Microbiol Spectr. 2021 Sep 3;9(1):e0004521. [Abstract]
- ACS Infect Dis. 2021 Jan 8;7(1):141-152. [Abstract]
- Vet Res. 2023 Dec 19;54(1):123. [Abstract]
- Dis Model Mech. 2021 Dec 1;14(12):dmm049145. [Abstract]
- J Pharm Biomed Anal. 2023 Oct 25:235:115658. [Abstract]
- Infect Immun. 2026 Feb 9:e0057425. [Abstract]
- SLAS Discov. 2020 Sep;25(8):895-905. [Abstract]
- bioRxiv. 2025 Nov 19:2025.11.19.689313. [Abstract]
- bioRxiv. 2025 Oct 17:2025.10.17.683099. [Abstract]
- Authorea. 2025 Sep 17.
- bioRxiv. 2025 July 04.
- bioRxiv. 2025 February 06.
- bioRxiv. 2024 Oct 30:2024.10.30.620736. [Abstract]
- Research Square Preprint. 2023 May 2.
- Zoonoses. 2023 Feb 2.
- Università Vita-Salute San Raffaele. 2022 Apr 08. 34.
- Research Square Preprint. 2022 Feb.
- University of Manitoba. 2022 Jan.
- Research Square Preprint. 2021 Nov.
- University of Madras. 2019, Jan.
Customer Validation & Images
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Microbiological Assay
-
Cell Imaging/Staining
All Antibiotic Isoforms
More
Biological Activity
Mtb F1FO-ATP synthase[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | CC50 |
>64 μg/mL
Compound: 1; TMC207,R207910
|
Cytotoxicity against human HeLa cells
Cytotoxicity against human HeLa cells
|
[PMID: 35636648] |
| Vero | CC50 |
>50 μg/mL
Compound: 1; TMC207,R207910
|
Cytotoxicity against African green monkey Vero cells
Cytotoxicity against African green monkey Vero cells
|
[PMID: 35636648] |
| Vero | IC50 |
>10 μg/mL
Compound: 1
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay
|
[PMID: 29107541] |
| Vero | IC50 |
>10 μg/mL
Compound: 1; TMC207
|
Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay
Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay
|
[PMID: 30891129] |
| Vero | IC50 |
>10 μg/mL
Compound: 1; TMC207, Sirturo
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay
|
[PMID: 30792104] |
| Vero | IC50 |
>10 μg/mL
Compound: 1; TMC207, Sirturo
|
Cytotoxicity against African green monkey Vero cells measured after 72 hrs by MTT assay
Cytotoxicity against African green monkey Vero cells measured after 72 hrs by MTT assay
|
[PMID: 30803745] |
| Vero | IC50 |
>10 μM
Compound: 2
|
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay
Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay
|
[PMID: 29259747] |
| Vero | IC50 |
4 μg/mL
Compound: 1; BDQ
|
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTS-PBS assay
Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTS-PBS assay
|
[PMID: 31810890] |
Bedaquiline inhibits the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L[2].
Among slowly growing mycobacteria (SGM), bedaquiline exhibits the highest activity against Mycobacterium avium with MIC50 and MIC90 values of 0.03 and 16 mg/L, respectively. Among rapidly growing mycobacteria (RGM), Mycobacterium abscessus subsp. abscessus (M. abscessus) and Mycobacterium abscessus subsp. massiliense (M. massiliense) seem more susceptible to bedaquiline than Mycobacterium fortuitum, with MIC50 and MIC90 values of 0.13 and >16 mg/L, respectively, for both species. Bedaquiline also shows moderate in vitro activity against NTM species[3].
Bedaquiline has an excellent in vitro activity against Mycobacterium tuberculosis, including multidrug resistant M tuberculosis[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 843663-66-1
-
Appearance Solid
-
Molecular Weight 555.50
-
Formula C32H31BrN2O2
-
Color White to yellow
-
SMILES
BrC1=CC=C(N=C(OC)C([C@H]([C@@](C2=CC=CC3=C2C=CC=C3)(O)CCN(C)C)C4=CC=CC=C4)=C5)C5=C1
-
Synonyms
TMC207; R207910
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (56)
-
Journal Impact Factor
-
Most Recent
-
Cell
2023 May 11;186(10):2176-2192.e22. PMID: 37137307 -
Nat Commun
Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours. [Abstract]2025 May 10;16(1):4366. PMID: 40348759
Bedaquiline purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]
Bedaquiline (BDQ) was effective on susceptible M. smegmatis already at 1× MIC (0.05 μg/mL).
-
Nat Commun
Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. [Abstract]2021 Jun 21;12(1):3816. PMID: 34155215
Bedaquiline purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 21;12(1):3816. [Abstract]
Bedaquiline (BDQ) (2.5 μg/mL, 24 h) significantly enhanced Pyrazinamide (PZA)/Pyrazinoic acid (POA) accumulation in intracellular Mtb.
-
Autophagy
2026 Mar 5. PMID: 41787744 -
Adv Sci (Weinh)
Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. [Abstract]2026 Apr;13(21):e13341. PMID: 41684301 -
Eur J Med Chem
Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase. [Abstract]2022 Nov 15:242:114639. PMID: 35973312 -
J Clin Microbiol
Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]2025 Aug 20:e0084125. PMID: 40833127
Bedaquiline purchased from MedChemExpress. Usage Cited in: J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
M. abscessus bedaquiline MIC90 values from TM4::GeNL DST, Sensititre RAPMYCO2 DST, MAB_2299c gene mutation-sMAB_4384 and MAB_2299c genotypes. Among the isolates tested, 35% (9/26) demonstrated Bedaquiline (BDQ) MICs greater than 0.5 µg/mL.
-
Int J Pharm
A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment. [Abstract]2024 Mar 25:653:123920. PMID: 38387819 -
Commun Biol
The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]2025 Oct 6;8(1):1425. PMID: 41053365
Bedaquiline purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]
Minimum Inhibitory Concentration (MIC) determination of the ΔcysE in comparison to WT and Complement strains against anti-TB drugs: Bedaquilline (BDQ) (7 days).
-
Commun Biol
Development of tolerance to bedaquiline by overexpression of trypanosomal acetate: succinate CoA transferase in Mycobacterium smegmatis. [Abstract]2025 Feb 6;8(1):187. PMID: 39915674 -
Pharmaceuticals (Basel)
Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC). [Abstract]2023 Sep 15;16(9):1309. PMID: 37765117 -
Front Cell Infect Microbiol
Imaging the NADH:NAD+ Homeostasis for Understanding the Metabolic Response of Mycobacterium to Physiologically Relevant Stresses. [Abstract]2016 Nov 8:6:145. PMID: 27878107 -
mBio
Bioenergetic Heterogeneity in Mycobacterium tuberculosis Residing in Different Subcellular Niches. [Abstract]2021 Jun 29;12(3):e0108821. PMID: 34060333 -
Antibiotics (Basel)
Differential Regulation of Oxidative Burst by First Line Drugs Used Against Multi Drug-Resistant Tuberculosis in Naïve Human Innate Immune Cells. [Abstract]2026 Jun 9;15(6):590. PMID: 42353714 -
Nanomedicine
3D spheroid model reveals enhanced efficacy of mannose-decorated nanoparticles for TB treatment. [Abstract]2025 Apr;20(8):777-789. PMID: 40099656 -
Antimicrob Agents Chemother
Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis. [Abstract]2025 Sep 11:e0079525. PMID: 40934365
Bedaquiline purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2025 Sep 11:e0079525. [Abstract]
Bedaquiline (BDQ) showed efficacy against Mtb in activated BMDMhs. Macrophages were infected with bacteria and treated with BDQ (0.63 and 2.5 μg/mL, 0-12 days).
-
Antimicrob Agents Chemother
Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China. [Abstract]2025 May 27:e0184724. PMID: 40422286 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 May 23:e0024925. PMID: 40407337 -
mLife
Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]2025 Apr 15;4(2):155-168. PMID: 40313980 -
Antimicrob Agents Chemother
Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]2024 Oct 29:e0105124. PMID: 39470195 -
Antimicrob Agents Chemother
2024 Oct 29:e0094524. PMID: 39470202 -
Antimicrob Agents Chemother
Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. [Abstract]2023 Feb 16;67(2):e0145922. PMID: 36688684 -
Front Microbiol
In vitro Antibacterial Activity of an FDA-Approved H+-ATPase Inhibitor, Bedaquiline, Against Streptococcus mutans in Acidic Milieus. [Abstract]2021 Feb 25;12:647611. PMID: 33717046 -
Antimicrob Agents Chemother
Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis. [Abstract]2021 Aug 17;65(9):e0095621. PMID: 34152815 -
Antimicrob Agents Chemother
Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis. [Abstract]2021 Mar 18;65(4):e01445-20. PMID: 33495223 -
Antimicrob Agents Chemother
TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. [Abstract]2020 Mar 24;64(4):e02404-19. PMID: 31964791 -
Antimicrob Agents Chemother
TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug's Uncoupler Activity. [Abstract]2020 Jan 27;64(2):e01540-19. PMID: 31712198 -
Antimicrob Agents Chemother
TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase. [Abstract]2019 Sep 23;63(10):e01191-19. PMID: 31358589 -
Front Microbiol
2018 Aug 15:9:1898. PMID: 30158918 -
J Biol Chem
High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against non-tuberculous mycobacteria in vitro and in vivo. [Abstract]2024 Feb;300(2):105618. PMID: 38176652 -
Microbiol Spectr
Evaluation of the post-antibiotic effect against Mycobacterium abscessus by a bioluminescence method. [Abstract]2026 Apr 7;14(5):e0380525. PMID: 41944630 -
ACS Infect Dis
Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease. [Abstract]2025 Apr 1. PMID: 40168319 -
ACS Infect Dis
Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects. [Abstract]2024 Sep 13;10(9):3222-3232. PMID: 39136125 -
ACS Infect Dis
Identification of Chemical Scaffolds Targeting Drug-Resistant and Latent Mycobacterium tuberculosis through High-Throughput Whole-Cell Screening. [Abstract]2024 Feb 9;10(2):513-526. PMID: 38238154 -
Microbiol Spectr
GaMF1.39's antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876. [Abstract]2023 Dec 12;11(6):e0228223. PMID: 37982630 -
ACS Chem Biol
Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]2022 Jan 21;17(1):39-53. PMID: 34908399 -
Microbiol Spectr
In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex. [Abstract]2021 Sep 3;9(1):e0004521. PMID: 34132613 -
ACS Infect Dis
Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis. [Abstract]2021 Jan 8;7(1):141-152. PMID: 33319550 -
Vet Res
2023 Dec 19;54(1):123. PMID: 38115043 -
Dis Model Mech
An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor. [Abstract]2021 Dec 1;14(12):dmm049145. PMID: 34643222 -
J Pharm Biomed Anal
Characterization of stress degradation products of bedaquiline fumarate and bedaquiline by LC-PDA and LC-MS. [Abstract]2023 Oct 25:235:115658. PMID: 37619292 -
Infect Immun
Mouse models of tuberculosis uniformly featuring hypoxic necrotic lesions and poor response to chemotherapy. [Abstract]2026 Feb 9:e0057425. PMID: 41660838 -
SLAS Discov
2020 Sep;25(8):895-905. PMID: 32567455 -
bioRxiv
Expanding the scope of Mycobacterium abscessus reference strains to improve pulmonary disease modeling. [Abstract]2025 Nov 19:2025.11.19.689313. PMID: 41332525 -
bioRxiv
Mouse Models Uniformly Featuring Human-like Lesions Harboring Drug-tolerant Mycobacterium tuberculosis. [Abstract]2025 Oct 17:2025.10.17.683099. PMID: 41279700 -
-
-
-
bioRxiv
2024 Oct 30:2024.10.30.620736. PMID: 39554043 -
-
-
-
-
-
-
Solvent & Solubility
DMSO : 12.5 mg/mL (22.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 0.5 mg/mL (0.90 mM); Clear solution
This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.5 mg/mL (0.90 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (788 KB)
- English - EN (788 KB)
- Français - FR (788 KB)
- Deutsch - DE (788 KB)
- Norwegian - NO (788 KB)
- Español - ES (788 KB)
- Swedish - SV (788 KB)
- Italian - IT (788 KB)
- Portuguese - PT (788 KB)
-
Handling Instructions (2659 KB)
References
[1]. Jang JC, et al. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. J Microbiol. 2017 Apr 20. [Content Brief]
[2]. Sarathy JP, et al. TBAJ-876 displays Bedaquiline-like mycobactericidal potency without retaining the parental drug's uncoupler activity. Antimicrob Agents Chemother. 2019 Nov 11. [Content Brief]
[3]. Chahine EB, et al. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014 Jan;48(1):107-15. [Content Brief]
[4]. Pang Y, et al. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017 Apr 24;61(5). [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.8002 mL | 9.0009 mL | 18.0018 mL | 45.0045 mL |
| 5 mM | 0.3600 mL | 1.8002 mL | 3.6004 mL | 9.0009 mL | |
| 10 mM | 0.1800 mL | 0.9001 mL | 1.8002 mL | 4.5005 mL | |
| 15 mM | 0.1200 mL | 0.6001 mL | 1.2001 mL | 3.0003 mL | |
| 20 mM | 0.0900 mL | 0.4500 mL | 0.9001 mL | 2.2502 mL |
Powered by Bioz